Polynucleotides and the Regenerative Turn: What "Bio-Stimulating" Actually Means

For most of the modern era of injectables, the logic was straightforward: a wrinkle is a deficit of volume, so you fill it. Hyaluronic acid filler sits in the tissue, adds bulk, and the line softens. The newer wave of aesthetic products works on a different premise. Rather than filling, they claim to stimulate — to prompt the skin to make more of its own collagen and elastin, repairing itself from within. This is the "regenerative turn", and its current poster children are biostimulatory fillers and polynucleotides.

It is a genuinely interesting shift, and not pure marketing. But "regenerative" and "bio-stimulating" are also exactly the kind of words that invite overclaiming, and the gap between the plausible mechanism and the proven result is where a careful reader needs to stand.

Two different things under one banner

It helps to separate what is actually being grouped together. Biostimulatory fillers — typically based on poly-L-lactic acid (PLLA) or calcium hydroxylapatite (CaHA) — are injected materials that, rather than simply adding volume, are designed to provoke a controlled tissue response that increases collagen production over weeks to months. The visible effect builds gradually and is meant to last longer than conventional filler because the result is partly the skin's own new collagen.

Polynucleotides are different. Derived from DNA fragments (often from fish sources), they are marketed not to add volume at all but to "prime" the skin — promoting fibroblast activity and binding water at a molecular level, improving hydration and quality. In 2026 they are increasingly positioned as a pre-treatment, used to prepare the skin before fillers or toxins rather than as a standalone reshaping tool. The market has also moved towards hybrid formulations that combine immediate volume from cross-linked hyaluronic acid with a longer-term biostimulatory component.

Grouping all of this as "regenerative aesthetics" is convenient for marketing but blurs real differences in mechanism, evidence, and what each can actually deliver.

The mechanism is plausible — which is exactly the trap

The regenerative story is appealing because it maps onto real biology. Skin does make collagen and elastin; fibroblasts do respond to stimulation; the body does repair itself. A product that nudges those processes is not a fantasy.

But this is precisely the situation where careful thinking matters most, because a plausible mechanism is the most persuasive form of weak evidence. The history of medicine is full of interventions that should have worked, on paper, and did not when tested properly — or worked far less well, or less durably, than the mechanism promised. "Stimulates your own collagen" is a sentence that sounds like proof and is actually a hypothesis. The questions that matter are the unglamorous ones: how large is the effect, how long does it last, how does it compare to simpler options, and how good is the evidence behind each claim?

For biostimulatory fillers, there is a reasonable and growing body of clinical use and evidence, and the products are well established. For polynucleotides, the commercial enthusiasm — and the "fastest-growing segment" projections — currently runs ahead of the high-quality comparative evidence, much as it does for exosomes. The reasonable position is interest tempered by the recognition that newer and more heavily marketed does not mean better proven.

"Natural" is not a safety argument

A recurring theme in regenerative marketing is the implication that because these products work with the body's own processes, they are inherently safer or more natural than older injectables. This deserves scepticism. Any injected product can cause the injection-related complications covered elsewhere in this section — infection, nodules, and, with fillers, vascular events. Biostimulatory fillers in particular can form nodules or lumps, and managing their complications can be more involved than for hyaluronic acid fillers, because — crucially — they are not reversible in the way HA fillers are. Hyaluronic acid can be dissolved with hyaluronidase if something goes wrong; PLLA and CaHA cannot simply be undone.

That single fact — reversibility — is one of the most important and least marketed distinctions in injectables. A product that builds its result slowly and lasts longer also, by the same logic, cannot be quickly removed if the result is wrong or a complication develops. "Long-lasting" and "hard to reverse" are two descriptions of the same property.

How to read the regenerative wave

The sensible frame is neither dismissal nor enthusiasm but specificity. Which product is actually being discussed — a biostimulatory filler, a polynucleotide, a hybrid — because they are not interchangeable? What is the specific, evidenced claim, as opposed to the category-level "regeneration" language? Is the product reversible if something goes wrong? And is the apparent novelty backed by clinical evidence, or mainly by mechanism and market projections?

Asked that way, the regenerative turn becomes what it actually is: a real and probably durable shift in how aesthetics works, carrying some genuinely useful tools, wrapped in language that runs ahead of the data and quietly omits the reversibility trade-off.

Practical takeaways

• "Regenerative aesthetics" groups together different things: biostimulatory fillers (PLLA, CaHA) that prompt collagen, and polynucleotides that aim to improve skin quality and hydration.
• The mechanisms are biologically plausible — which makes overclaiming easy; plausible is not the same as proven.
• Biostimulatory fillers are reasonably established; polynucleotide marketing currently runs ahead of high-quality comparative evidence.
• "Natural" or "works with your body" is not a safety guarantee — these are still injections with injection risks.
• Biostimulatory fillers are generally not reversible, unlike hyaluronic acid fillers; long-lasting also means hard to undo.

What this doesn't mean

This is not a dismissal of regenerative products — some are well established and genuinely useful, and the underlying science is real. It is a caution about the language: "regenerative" and "bio-stimulating" describe a mechanism, not a level of proof or safety, and the reversibility trade-off is rarely mentioned in the marketing.

When to seek medical advice

If you develop lumps, nodules, persistent swelling, pain, or signs of infection after any injectable — including biostimulatory fillers or polynucleotides — seek medical advice, and tell the clinician exactly which product was used, since management differs by product and some are not reversible. Before any injectable, a qualified clinician can help you weigh the specific evidence and trade-offs for your situation.

A closing thought

The move from filling lines to stimulating biology is one of the more interesting developments in aesthetics, and some of these tools will likely earn a lasting place. But the words doing the selling — regenerative, bio-stimulating, natural — are precisely the ones that reward scepticism, because they describe how something is meant to work, not how well it has been shown to. And the quietest fact of all, that the longer-lasting products are also the hardest to reverse, is the one worth carrying into any decision.

Further reading and sources

• Exosomes in aesthetic medicine: an overview — Aesthetic Surgery Journal (context on the regenerative category and the state of its evidence)
• British Association of Dermatologists — patient information on cosmetic procedures
• British College of Aesthetic Medicine — guidance on safe injectable practice
• House of Commons Library — the regulation of non-surgical cosmetic procedures in England

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.